Calidi Biotherapeutics Stock Soars 174.93% on Precision Medicine Hype

On July 9, 2025, Calidi's stock surged by 174.93% in pre-market trading, marking a significant milestone for the company.

Calidi Biotherapeutics has been at the forefront of developing a precision genetic medicine platform designed to revolutionize cancer treatment. The company's innovative approach utilizes engineered viruses to precisely deliver genetic medicine to cancer sites, addressing both primary tumors and metastatic sites. This technology has the potential to transform the landscape of cancer treatment, given the projected 35 million annual cancer cases by 2050.

This year, Calidi has presented compelling preclinical data at two of the most influential oncology conferences, further validating the potential of its platform. The company's efforts have garnered attention and support, positioning it as a leader in the field of precision genetic medicine.